Pdf primary small cell carcinoma of the prostate gland is a rare disease entity with a poor prognosis. Gene expression signatures of neuroendocrine prostate. Tumour cell secretome in chemoresistance and tumour. Poorly differentiated smallcelltype neuroendocrine carcinoma of. Understanding how cancer cells overcome chemotherapy induced cell death is critical in promoting patient survival. Results of a phase ii study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small cell carcinoma of the prostate. Primary small cell carcinoma of the prostate is a rare and very aggressive disease with a poor prognosis, even in its localized form. Amato rj1, logothetis cj, hallinan r, ro jy, sella a, dexeus.
Pure or combined with ordinary ductal adenocarcinoma diagnosis restricted to cases having either pure or mixed with an adenocarcinoma component, where the cells resemble small cell carcinoma of the lung and elsewhere histologically. Small cell carcinomas are often positive for ne markers. Small cell prostate carcinoma scpc is a lethal variant of prostate cancer. Primary small cell carcinoma of the prostate has been described as occurring after a diagnosis of adenocarcinoma of the prostate schron et al, 1984, as a combination of the two histologies at the. Smallcell prostate carcinoma scpc is a lethal variant of prostate cancer. Genitourinary small cell cancer guscc is a rare malignancy. The nccn guidelines panel for cervical cancer screening endorses the following guidelines for the prevention and early detection of cervical cancer. Approximately 4050% of men with prostatic sccs have a history of. Since its first description, epsmcc has been reported in virtually all anatomical sites. In the limited studies available on the management of prostatic scc, the recommended firstline treatment is chemotherapy with a combined use of cisplatin and etoposide. Prostatic metastasis of pulmonary large cell neuroendocrine carcinoma.
Small cell carcinomas sccs are aggressive neoplasms commonly associated with a pulmonary origin. Jan 14, 2015 small cell carcinoma smcc is a distinct clinicopathological entity first described in the lung. Among these sites, approximately 10% of extrapulmonary scc cases occur in the prostate and are associated with a poor mortality with a median survival of 10. One emerging mechanism of chemoresistance is the tumour cell secretome tcs, an array of protumorigenic factors released by tumour cells. Prostatic smallcell carcinoma pscc is a rare tumor that accounts for 0. We report a case of primary squamous cell carcinoma involving the prostate in an 80yearold man with a history of benign prostatic hyperplasia, the patient underwent a transurethral resection prostate turp procedure for progressive urinary obstruction. This means a biopsy or transurethral resection of the.
Small cell carcinoma scc of the prostate is a highgrade malignant neoplasm with neuroendocrine differentiation and accounts for only 0. Histologically, prostatic sccs of the prostate are part of a spectrum of. Small cell carcinoma of the prostate pubmed central pmc. The large majority of prostate tumours is represented by the adenocarcinoma histotype. Extrapulmonary small cell carcinoma epsmcc morphologically indistinguishable from small cell lung cancer sclc was first reported in 1930. Smallcell prostate cancer is a rare disorder completely different from the more common variant of adenocarcinoma, and represents a very aggressive disease with a poor prognosis. Cureus small cell cancer of the bladder and prostate. It represents approximately 15% of all bronchogenic carcinoma.
This means a biopsy or transurethral resection of the prostate is needed to diagnose small cell prostate cancer. The usual treatment for pscnc is systemic chemotherapy, with or. Prostatic small cell carcinoma pscc is a distinct clinical phenotype of prostate. Primary small cell carcinoma of the prostate scpca is a rare pathologic entity with unique clinical features and a poor prognosis. Pdf primary small cell carcinoma of the prostate gland is a rare disease entity with a poor.
Clinicopathological analysis on small cell carcinoma of the. Histologically, small cell carcinoma of the prostate is characterized by a pattern similar to small cell carcinoma of the lung. A survey of these lesions is presented, including usual pca with focal ne marker. Docetaxel, when used with or without prednisone, was the first chemotherapy drug proven to help patients live longer with advanced prostate cancer. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually. The patient was started on palliative chemotherapy with carboplatinetoposide every 3 weeks. The large majority of prostate tumours is represented by the adenocarcinoma histotype up to 95%, while small cell, squamous cell, transitional cell, signet ring cell, mucinous and mixed types carcinomas occurs in less than 2% of cases 2, 3. Prostate cancer is the second most frequently diagnosed type of cancer and the sixth leading cause of cancerrelated mortality in men, accounting for 14% 903,500 of total new cancer. We report a case of primary squamous cell carcinoma involving the prostate in an 80. Although sometimes large cell neuroendocrine carcinoma in prostate presents as metastases from.
Pure smallcell carcinoma scc of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Diagnostic testing, physical findings, and icd9cm coding diagnostic testing. Treatment of small cell carcinoma and prostate cancer with neuroendocrine differentiation. However, albeit rare, extrapulmonary scc epscc can occur in a variety of sites. Aug 01, 2019 chemotherapy for prostate cancer chemotherapy chemo uses anticancer drugs injected into a vein or given by mouth. These drugs travel through the bloodstream to reach cancer.
We herein report a case of prostatic metastasis of pulmonary large cell neuroendocrine carcinoma lcnec. Although prostate cancer is a common cancer in men, there are different types of prostate cancer, and some of these are rare. Smallcell carcinoma scc of the prostate is a rare subtype of prostate cancer characterized by an aggressive clinical course. Small cell carcinoma of the prostate treated with amrubicin. We managed a case of primary small cell carcinoma of the prostate. Treating extended prostatic small cell neuroendocrine carcinoma. The bones, liver, regional and distant lymph nodes are the most common sites of metastasis of small cell carcinoma of the prostate. In conclusion, considering lcnec as a differential diagnosis in patients with prostate cancer is important. Prostate cancer is the most common malignancy of men in the united states. Treated prostate carcinoma other uncommon carcinomas. However, albeit rare, extrapulmonary scc can occur in a variety of sites with an incidence in north. These findings suggest that the inhibitory effect of.
Histology and immunohistochemistry shows a tumour which is indistinguishable from small cell lung carcinoma sclc. Most cases are diagnosed at advanced stage due to early metastasis. From 2005 to 2010, there were a total of three cases of scc at our hospital. Primary squamous cell carcinoma of the prostate wang. A 60yearold male patient presented with dysuria, pollakiuria, and nocturia of about 1year duration. Smallcell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal. Clinicopathological analysis on small cell carcinoma of. Platinumbased chemotherapy for variant castrateresistant. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Initial radiological examinations of the patient revealed a pelvic tumor associated with bilateral hydronephrosis, pelvic lymph node swelling, and lumbar vertebral bone metastases.
Neuroendocrine cells do not produce psa, so a psa test wont help to diagnose small cell prostate cancer. Up to this point, chemotherapys role in prostate cancer has been only for palliation. Not until recently has chemotherapy been used as a viable treatment option for patients with hrpc. Small cell carcinoma smcc is a distinct clinicopathological entity first described in the lung. Chemotherapy for nonsmall cell lung cancer chemotherapy chemo is treatment with anticancer drugs that may be injected into a vein or taken by mouth.
Small cell carcinoma of the prostate is a very rare and aggressive type of prostatic cancer. Case of smallcell prostate cancer with a metastasis to. Nonsmall cell lung cancer chemotherapy chemo side effects. Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A total of 21 patients with metastatic small cell carcinoma of the prostate was treated with combination chemotherapy, either following initial hormonal therapy 15 or as initial therapy 6. Modeling a lethal prostate cancer variant with smallcell. Lung cancer metastases to the prostate are uncommon, and are usually found incidentally during autopsy. Histologically, prostatic sccs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to sccs of the lungs. Papandreou cn, daliani dd, thall pf, tu sm, wang x. Small cell prostate cancer scpc is a rare pathology, with aggressive behaviour and a high tendency to metastasize. Small cell carcinoma of the prostate presenting with skin. This case report describes a 77yearold man with a large cell neuroendocrine carcinoma lcnec of the lung and metastases from this primary cancer in the prostate. It now can be used to decrease pain, and for the first time a chemotherapy based regimen has been shown to also increase survival.
Pure small cell carcinoma scc of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Chemotherapy for small cell carcinoma of prostatic origin. Chemotherapy for prostate cancer chemotherapy chemo uses anticancer drugs injected into a vein or given by mouth. Understanding how cancer cells overcome chemotherapyinduced cell death is critical in promoting. The prognosis of small cell carcinoma of the prostate is poor. Chemotherapy for non small cell lung cancer chemotherapy chemo is treatment with anticancer drugs that may be injected into a vein or taken by mouth. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic scc. Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. Pathology outlines small cell neuroendocrine carcinoma. Resistant prostate cancer clinical cancer research. Gene expression signatures of neuroendocrine prostate cancer. Chemotherapy can be used to treat rare types of prostate cancer, such as small cell prostate cancers. Of the patients 62% had pure small cell carcinoma, whereas 8 38% had mixed histology of small cell carcinoma and adenocarcinoma.
Most of the published data on how to manage this malignancy is based on institutional experience. Cyclophosphamide vac chemotherapy at 3 weekly intervals. Distinct genetic alterations in small cell carcinoma from. Chemotherapy for prostate cancer canadian cancer society. Using chemotherapy may reduce the need for radiation. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Neuroendocrine ne differentiation in tumors of the prostate or in the setting of prostate cancer pca is rare. May 12, 2014 small cell carcinoma of the prostate is a very rare and aggressive type of prostatic cancer. However, albeit rare, extrapulmonary scc epscc can occur in a variety of sites with an incidence in north america approximated to be 0. Studies have suggested that primary pscc cases are frequently. Small cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Neuroendocrine tumors of the prostate modern pathology.
Dexeus from the department of medical oncology, university of texas m. He was offered systemic chemotherapy but refused it. These drugs travel through the bloodstream to reach cancer cells in most parts of the body. Extrapulmonary small cell cancer epscc is a rare malignancy and was first introduced in the medical literature as a separate clinicopathological disease entity in 1930.
Results of a phase ii study with doxorubicin, etoposide, and cisplatin in. This program was designed to help urology residents and fellows familiarize themselves with the pathologic features of common urologic entities. A study retrospectively assessed data of 30 cases with prostate small cell carcinoma and reported a 54month diseasefree survival with systemic chemotherapy and antiandrogen therapy in a case with pure small cell prostate carcinoma and widespread metastatic disease. Diagnosing and treating smallcell carcinomas of prostatic origin. Prostatic metastasis of pulmonary large cell neuroendocrine. In addition, in 30% of cases, the primary focus cannot be identified 2. A useful treatment for patients with advanced mixedtype small cell. Smallcell carcinoma scc, which typically presents as an aggressive lung malignancy, is a rare diagnosis within the.
Anderson cancer center, houston, texas abstract a total of 21 patients with metastatic small cell carcinoma. In contrast, the ec 50 values of the lncap and du145 human prostate cancer cell lines were approximately 20fold higher figure s5b. Ductal adenocarcinoma small cell carcinoma urothelial carcinoma of the prostate carcinoma with squamous differentiation basal cell carcinoma adenoid cystic carcinoma sarcomatoid carcinoma carcinosarcoma mesenchymal and other tumors. These drugs travel through the bloodstream and reach most parts of the body. In anemia, a lowered level of red blood cells may result in fatigue and other symptoms such as dizziness or headache.
Small cell carcinoma scc of the prostate is a highgrade malignant. However, albeit rare, extrapulmonary scc can occur in a variety of sites with an incidence in north america approximated to be 0. Squamous cell carcinoma of the prostate is very rare, making less than 1% of all prostatic malignancies. Welcome to the updated version of pathology for urologists. Clinical features characteristic of smallcell prostate carcinoma scpc, anaplastic, often emerge during the progression of prostate cancer. The following drug combinations are used to treat prostate cancer if an adenocarcinoma the most common type of prostate cancer changes into a more aggressive type of cancer called a small cell carcinoma of the prostate. Pure or combined with ordinary ductal adenocarcinoma diagnosis restricted to cases having either pure or mixed with an adenocarcinoma component, where the cells resemble smallcell. Chemoresistance is a major factor driving tumour relapse and the high rates of cancerrelated deaths. The pathological diagnosis was small cell carcinoma originating in the prostate, based on positive. Small cell prostate cancer constitutes less than 1% of all prostate cancers and has a poor prognosis. Although consensus has not been reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and. These findings suggest that the inhibitory effect of cd532 is more specific for nmycdriven prostate cancer.
We present a case of a patient diagnosed with pure scpca treated with. Small cell carcinoma scc, which typically presents as an aggressive lung malignancy, is a rare diagnosis within the. Pdf small cell carcinoma of the prostate researchgate. Androgen ablation therapy is ineffective, the frequently observed chemotherapy. Small cell carcinomas are often positive for ne markers chromogranina, synaptophysin and nse although one or more of these markers may be negative in any given case. Small cell carcinoma of the bladder sccb is rare, highly aggressive and diagnosed mainly at advanced stages. Apr 17, 2007 up to this point, chemotherapy s role in prostate cancer has been only for palliation. One theory suggests that small cell carcinomas of the prostate arise from amine precursor uptake decarboxylation cells of local endodermal origin. Small cell prostate cancer is aggressive and can spread quickly to other parts of the body.
366 384 615 616 576 1231 557 701 201 1026 1309 945 1211 331 516 509 1302 438 1212 105 235 368 115 938 1381 427 4 6 1041 353